Infervision, a Chinese artificial intelligence (AI) start-up specialized in medical imaging technology, has completed a series B round of financing led by led by Qiming Venture Partners. The round also included Genesis Capital and Sequoia Capital, with China Taihecap served as the exclusive financial advisor.

Beijing Infervision is an artificial intelligence high-tech company committed to applying deep learning technology to assist medical image diagnosis as efficient and accurate solutions. Infervision effectively uses various types of medical data to create clinically valued products and promotes precision analysis in the medical field especially in assisted image diagnosis. Based on years of research preparation, Infervision launched the world first "Infervision - artificial intelligence precise healthcare platform", and is the first to release intelligent X-ray assisted diagnosis products and intelligent CT assisted diagnosis products. These products are already in trials at Shanghai Changzheng Hospital, Tongji Medical College of HUST in Wuhan, and Dalian Zhongshan Hospital.

The company is also engaged in academic research and has established a deep cooperative relationship with top institutions in Chinese Radiology, combining both medical science and medical technology while laying a solid foundation for artificial intelligence breakthroughs in the medical field. Infervision has established cooperative business partnerships with close to 20 Tertiary Grade A hospitals including Peking Union Medical College Hospital, Shanghai Changzheng Hospital, Tongji Medical College of HUST in Wuhan and Dalian Zhongshan Hospital, and has successfully broken the barriers between medical data, technology, and application scenarios, creating a unique system of an artificial intelligence computing platform and precise healthcare intelligence system.